Sustained Virologic Response Following a Shortened Course of Direct-Acting Antiviral Therapy in an HIV/HCV Co-Infected Patient With Previous Treatment Experience: A Case Report.

J Pharm PractDec 19, 2025 (epub)

Natasha Bhutani, Yoona Lee, Maria A Longo et al.

✦ AI-curated · Sources linked

Case in brief

A 47-year-old treatment-experienced man with HIV and chronic HCV had completed 10 weeks of sofosbuvir-velpatasvir before starting sofosbuvir-velpatasvir-voxilaprevir. He took the triple regimen for approximately 4 weeks, then was lost to follow-up for 3 months. HCV testing showed sustained virologic response 12 weeks after treatment (SVR12), despite the shortened course. The report highlights that virologic response was documented after incomplete triple-direct-acting antiviral therapy in this individual.

What made this case unusual

SVR12 followed approximately 4 weeks of triple therapy in a treatment-experienced patient who had already received 10 weeks of sofosbuvir-velpatasvir.

Diagnostic / clinical pearl

For patients lost to follow-up or who did not complete HCV therapy, assess HCV RNA for SVR12 before considering treatment re-initiation.

Source

Published in J Pharm Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.